Because tirzepatide was only approved by the FDA in mid-2022 for type 2 diabetes, the ability to rigorously analyze its use (on- and off-label) for a broad population of patients with overweight or obesity, not just a subset captured in insurance databases, has the power to greatly improve our understanding of how these agents are being used in every day practice and the effect that theyre having. This research was conducted using Truveta, which offers the most complete, timely, and clean regulatory-grade electronic health record (EHR) data from more than 100 million patients across more than 30 US health systems
Dose adjustments are made based on your response and tolerance
The results suggest that, with proper supervision, a protein-rich diet, regular resistance training, and guidance from a trained medical provider, patients can decrease fat mass while minimizing muscle loss. We found that, under close supervision and regular follow-up from an obesity medicine specialist, patients were able to lose fat mass with only a minimal decline in muscle mass, Peralta-Reich added
Characterization and crystal structure of a novel zearalenone hydrolase from Cladophialophora bantiana
